ASPEN position paper clinical role for alternative intravenous fat emulsions
Revision as of 01:05, 9 August 2022 by 179.215.124.0 (talk) (Created page with "== Target Article == ASPEN position paper clinical role for alternative intravenous fat emulsions; VW Vanek, DL Seidner, P Allenae; 2012; doi_citing_unknown == Retraction == Retraction: Sudbø J et al. DNA Content as a Prognostic Marker in Patients with Oral Leukoplakia. N Engl J Med 2001;344:1270-8 and Sudbø J et al. The Influence of Resection and Aneuploidy on Mortality in Oral Leukoplakia. N Engl J Med 2004;350:1405-13; Sudbø J et al. ; 2006-11-2 ; https://doi.org/1...")
Target ArticleEdit
ASPEN position paper clinical role for alternative intravenous fat emulsions; VW Vanek, DL Seidner, P Allenae; 2012; doi_citing_unknown
RetractionEdit
Retraction: Sudbø J et al. DNA Content as a Prognostic Marker in Patients with Oral Leukoplakia. N Engl J Med 2001;344:1270-8 and Sudbø J et al. The Influence of Resection and Aneuploidy on Mortality in Oral Leukoplakia. N Engl J Med 2004;350:1405-13; Sudbø J et al. ; 2006-11-2
Citation pieceEdit
Note: Open to append information.